Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

152 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Cardiovascular outcomes in the Irbesartan Diabetic Nephropathy Trial of patients with type 2 diabetes and overt nephropathy.
Berl T, Hunsicker LG, Lewis JB, Pfeffer MA, Porush JG, Rouleau JL, Drury PL, Esmatjes E, Hricik D, Parikh CR, Raz I, Vanhille P, Wiegmann TB, Wolfe BM, Locatelli F, Goldhaber SZ, Lewis EJ; Irbesartan Diabetic Nephropathy Trial. Collaborative Study Group. Berl T, et al. Among authors: esmatjes e. Ann Intern Med. 2003 Apr 1;138(7):542-9. doi: 10.7326/0003-4819-138-7-200304010-00010. Ann Intern Med. 2003. PMID: 12667024 Clinical Trial.
Predictors of cardiovascular events in patients with type 2 diabetic nephropathy and hypertension: a case for albuminuria.
Anavekar NS, Gans DJ, Berl T, Rohde RD, Cooper W, Bhaumik A, Hunsicker LG, Rouleau JL, Lewis JB, Rosendorff C, Porush JG, Drury PL, Esmatjes E, Raz I, Vanhille P, Locatelli F, Goldhaber S, Lewis EJ, Pfeffer MA. Anavekar NS, et al. Among authors: esmatjes e. Kidney Int Suppl. 2004 Nov;(92):S50-5. doi: 10.1111/j.1523-1755.2004.09213.x. Kidney Int Suppl. 2004. PMID: 15485418 Free article. Review.
Impact of achieved blood pressure on cardiovascular outcomes in the Irbesartan Diabetic Nephropathy Trial.
Berl T, Hunsicker LG, Lewis JB, Pfeffer MA, Porush JG, Rouleau JL, Drury PL, Esmatjes E, Hricik D, Pohl M, Raz I, Vanhille P, Wiegmann TB, Wolfe BM, Locatelli F, Goldhaber SZ, Lewis EJ; Collaborative Study Group. Berl T, et al. Among authors: esmatjes e. J Am Soc Nephrol. 2005 Jul;16(7):2170-9. doi: 10.1681/ASN.2004090763. Epub 2005 Jun 1. J Am Soc Nephrol. 2005. PMID: 15930097
Independent and additive impact of blood pressure control and angiotensin II receptor blockade on renal outcomes in the irbesartan diabetic nephropathy trial: clinical implications and limitations.
Pohl MA, Blumenthal S, Cordonnier DJ, De Alvaro F, Deferrari G, Eisner G, Esmatjes E, Gilbert RE, Hunsicker LG, de Faria JB, Mangili R, Moore J Jr, Reisin E, Ritz E, Schernthaner G, Spitalewitz S, Tindall H, Rodby RA, Lewis EJ. Pohl MA, et al. Among authors: esmatjes e. J Am Soc Nephrol. 2005 Oct;16(10):3027-37. doi: 10.1681/ASN.2004110919. Epub 2005 Aug 24. J Am Soc Nephrol. 2005. PMID: 16120823 Clinical Trial.
[Prevalence of nephropathy in type I diabetes].
Esmatjes E, Castell C, Goday A, Montanya E, Pou JM, Salinas I, Simó R, González MT, Tresserras R, Lloveras G. Esmatjes E, et al. Med Clin (Barc). 1998 Jan 17;110(1):6-10. Med Clin (Barc). 1998. PMID: 9527979 Spanish.
152 results